CHARLOTTE, N.C., Nov. 29, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Piper Jaffray 23rd Annual Healthcare Conference at 11:30 AM ET on November 30, 2011 at New York Palace Hotel.
Dr. Simon Pedder, Chelsea's Chief Executive Officer, will provide a brief overview of the company's...
CHARLOTTE, N.C., Nov. 17, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for NORTHERA™ (droxidopa), an orally active synthetic precursor of norepinephrine, for the treatment of symptomatic neurogen...
CHARLOTTE, N.C., Nov. 2, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported financial results for the third quarter 2011 and presented a quarterly update on the Company's development progress. Chelsea's management team will host a conference call this afternoon at 4:30 PM EDT to discuss these results.Recent Hig...
Mid-Range Dose of CH-4051 Demonstrates Similar Comparable Efficacy and Improved Safety and Tolerability Compared to Standard Dose of MethotrexateData From 0.3 mg and 1.0 mg CH-4051 Arms Suggest Dose EffectHigh-Dose Arms Now Fully Enrolled With Topline Results Expected in Second Quarter 2012
CHARLOTTE, N.C., Nov. 2, 2011 (GLOBE NEWSWIRE) -- Chel...
CHARLOTTE, N.C., Oct. 27, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release third quarter results for the period ended September 30, 2011 after the market closes on Wednesday, November 2, 2011. Chelsea management will host a conference call and live webcast to discuss these financial resu...
CHARLOTTE, N.C., Sept. 28, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market NORTHERA™ (droxidopa), an orally active synthetic precursor of norepinephrine, for the treatment of sympto...
CHARLOTTE, N.C., Sept. 7, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 13th Annual Rodman & Renshaw Global Healthcare Investment Conference at 11:15 AM on September 13, 2011 at the Waldorf-Astoria in New York.
Keith Schmidt, Chelsea's vice president for marketing and sales, will ...
CHARLOTTE, N.C., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that the United States Patent and Trademark Office has issued U.S. Patent No. 8,008,285 entitled "Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia." The claims of the patent are related to metho...
CHARLOTTE, N.C., Aug. 10, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Wedbush 2011 Life Sciences Management Access Conference at 10:35 AM ET on August 17, 2011 at the Le Parker Meridien in New York.
Dr. Simon Pedder, Chelsea's president and chief executive officer, will provide ...
CHARLOTTE, N.C., Aug. 8, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has successfully reached its target enrollment of 120 patients in its Phase II trial of droxidopa for the treatment of fibromyalgia. Top-line results of the trial are expected by the end of the year.
"We are delighted to have reached our tar...
Northera™ (droxidopa) New Drug Application for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension on Track for Submission in Third Quarter 2011Unblinded Interim Efficacy Data From CH-4051 Phase II Trial in Rheumatoid Arthritis Expected in September 2011Company to Host Conference Call at 4:30 PM EDT
CHARLOTTE, N.C., July 26, 2...
CHARLOTTE, N.C., July 26, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced positive top-line results of an investigator-led Phase II clinical study of droxidopa in combination with carbidopa in adults with attention deficit hyperactivity disorder (ADHD).
The single-center, 12-week study enrolled 20 patie...
CHARLOTTE, N.C., July 20, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release second quarter results for the period ended June 30, 2011 after the market closes on Tuesday, July 26, 2011. Chelsea management will host a conference call and live webcast to discuss these financial results and p...
CHARLOTTE, N.C., June 20, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced the successful completion of its dedicated QTc study of NORTHERA (droxidopa), an orally active synthetic precursor of norepinephrine, the company's lead product for which it plans to seek approval for the treatment of symptomatic neur...
Northera Treatment Provides Durable Beneficial Effects on both Systolic Blood Pressure and the Symptoms of NOH in Patients with Multiple System AtrophyRobust Symptomatic Benefit of Northera Associated with Fewer Falls in Patients with NOH and Parkinson's Disease Prone to FallingImprovements in MDS-UPDRS and Hoehn & Yahr Scores Seen with Northera Tr...
Preparing to File Northera New Drug Application in Third Quarter 2011Opening Enrollment into High Dose Arms of Phase II Trial of CH-405 for Treatment of Rheumatoid Arthritis and On Track to Report Un-blinded Interim Efficacy Data in Third Quarter 2011Company to Host Conference Call at 4:30 PM ET
CHARLOTTE, N.C., May 9, 2011 (GLOBE NEWSWIRE) -- ...
CHARLOTTE, N.C., May 9, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that an independent Data Safety Monitoring Board (DSMB) recently met to review patient safety data for Chelsea's Phase II trial of CH-4051 in rheumatoid arthritis (RA) and recommended that each on-going arm of the study continue as plan...
Dr. Robert Hauser to Present Late Breaking Poster Highlighting Efficacy of Northera in Patients with Neurogenic Orthostatic Hypotension associated with Parkinson's Disease on June 8th 2011Dr. Gregor Wenning to Present Poster on Safety and Efficacy of Northera in Multiple System Atrophy on June 8th 2011Chelsea to Sponsor Symposium Reviewing Results ...
CHARLOTTE, N.C., April 28, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release first quarter results for the period ended March 31, 2011 after the market closes on Monday, May 9, 2011. Chelsea management will host a conference call and live webcast to discuss these financial results and pro...
CHARLOTTE, N.C., April 27, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 36th Annual Deutsche Bank Healthcare Conference at 2:50 PM ET on Monday, May 2, 2011 at the InterContinental Hotel in Boston.
Dr. Simon Pedder, Chelsea's president and chief executive officer, will provide a ...
Delicious
Digg
Facebook
LinkedIn
Twitter
